phrykt

Champions Oncology, Inc. (CSBR): who owns it and who trades it

As of Nov 12, 2026, no open-market insider purchases or sales of CSBR were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Champions Oncology

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CSBR

27 funds and institutions reported CSBR shares worth $36.4M at the end of Q2 2026, about 42% of the company. The largest holder is Battery Management Corp. with 17.4%.

Funds and institutions (13F) 42%Everyone else 58%

10 largest owners, by share of the company

Battery Management Corp.17.4%
NEA Management Company, LLC12.3%
Vanguard Capital Management LLC2.2%
Tocqueville Asset Management L.P.2.1%
Morgan Stanley1.7%
Bank of America Corp1.5%
Renaissance Technologies LLC1.0%
BlackRock, Inc.0.9%
Mink Brook Asset Management LLC0.8%
Geode Capital Management, LLC0.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Battery Management Corp.2.42M17.44%$14.9MNo change
NEA Management Company, LLC1.71M12.34%$10.6MNo change
Vanguard Capital Management LLC301,3532.17%$1.9M+1%
Tocqueville Asset Management L.P.295,6582.13%$1.8M-8%
Morgan Stanley235,4001.70%$1.5M-3%
Bank of America Corp214,0581.54%$1.3M+880%
Renaissance Technologies LLC139,0391.00%$856K-4%
BlackRock, Inc.129,8480.94%$800K+5%
Mink Brook Asset Management LLC111,3380.80%$686KNo change
Geode Capital Management, LLC76,3000.55%$470K-1%
HighTower Advisors, LLC41,9010.30%$258K+19%
Vanguard Fiduciary Trust Co33,2390.24%$205K+1%
Northern Trust Corp27,9100.20%$172K-39%
State Street Corp26,2030.19%$161KNo change
Cambridge Investment Research Advisors, Inc.24,5040.18%$150K+100%
Bank of New York Mellon Corp21,6140.16%$133KNo change
Acadian Asset Management LLC20,5230.15%$125K-4%
Citadel Advisors LLC18,2950.13%$113KNew
Essex Investment Management Co LLC18,2210.13%$112K-0%
Mesirow Financial Investment Management, Inc.15,8000.11%$97.3KNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No CSBR insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CSBR short interest

Low short interest. 0.5% of CSBR shares are sold short: about 1 share in 193. Over the last 12 reports the number of shares short went down 15%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 72,290 CSBR shares were sold short, 0.5% of the shares outstanding, down 6.9% from the report before. At the average daily volume of 8,455 shares, buying them all back would take about 8.6 trading days (days to cover).

Shares short, % of all shares

0.52%May 15Oct 300.63%

Days to cover

8.6May 15Oct 3013.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202672,2900.52%-7%8,4558.6
Oct 15, 202677,6510.56%+9%8,2719.4
Sep 30, 202670,9610.51%+4%16,1424.4
Sep 15, 202668,4630.49%-8%12,3945.5
Aug 31, 202674,2900.53%+0%6,17612.0
Aug 14, 202673,9980.53%-3%12,3866.0
Jul 31, 202676,1640.55%+1%8,4669.0
Jul 15, 202675,5660.54%-2%9,6247.8
Jun 30, 202676,9170.55%-2%7,35910.4
Jun 15, 202678,5310.57%-3%6,24112.6
May 29, 202680,6010.58%-5%12,2456.6
May 15, 202684,7260.61%+1%11,1797.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Champions Oncology company events

Champions Oncology filed 6 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 16, 2026.

  1. Oct 16, 2026VoteReported shareholder vote results. Filing
  2. Sep 10, 2026ResultsReleased financial results. Filing
  3. Jul 27, 2026ResultsReleased financial results. Filing
  4. Mar 30, 2026LeadershipThe Board of Directors of Champions Oncology, Inc. accepted the resignation of Dr. Philip Breitfeld as a member of the Board and appointed Dr. Brian Alexander as a director of the Company to fill the vacancy created by Dr. Breitfeld’s resignation. Filing
  5. Mar 12, 2026ResultsReleased financial results. Filing
  6. Dec 15, 2025ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Champions Oncology financials

Famous investors that hold CSBR

1 of the 50 well-known investors we track reported holding CSBR in their latest 13F filing. The largest position is Jim Simons's, worth $648K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026129,639$648K0.0%-7%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Champions Oncology, Inc. (CSBR) stock

Who owns the most CSBR stock?

The largest reported owner of Champions Oncology, Inc. (CSBR) is Battery Management Corp., with 17.4% of the company. In total, 27 funds and institutions reported holding CSBR at the end of Q2 2026, together about 42% of the shares. See the largest owners.

Are CSBR insiders buying or selling?

No CSBR insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in CSBR?

As of Oct 30, 2026, 72,290 CSBR shares were sold short, 0.5% of the shares outstanding, down 6.9% from the report before. At the average daily volume of 8,455 shares, buying them all back would take about 8.6 trading days (days to cover). See the history.

Which famous investors hold CSBR?

1 of the 50 well-known investors we track reported CSBR in their latest 13F filing, including Jim Simons. The largest position is worth $648K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.